Skip to navigation Skip to content

Progressive fibrosing interstitial lung disease (PF-ILD) Program in Pharmaceutical Benefits Scheme 012-22042647

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised nintedanib for patients with progressive fibrosing interstitial lung disease (PF-ILD).

PF-ILD and listing dates

PF-ILD is part of a large group of lung disorders. It causes progressive scarring (fibrosis) of the lung tissue.

Listing date:

  • nintedanib - 1 May 2022

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS Schedule and the Services Australia website.

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs